THREE YEAR MORTALITY ANALYSIS AMONG HEMODIALYSIS PATIENTS: A SINGLE CENTER STUDY FROM MULTAN INSTITUTE OF KIDNEY DISEASES

MR ASGHAR; S ANWAR; K BASHIR; N SALEEM

doi:10.54112/bcsrj.v2023i1.189

Authors

MR ASGHAR Department of Nephrologist, Multan Institute of Kidney Diseases Multan, Pakistan
S ANWAR Department of Nephrology, Multan Institute of Kidney Diseases Multan, Pakistan
K BASHIR Department of Nephrologist, Multan Institute of Kidney Diseases Multan, Pakistan
N SALEEM Department of Nephrologist, Multan Institute of Kidney Diseases Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.189

Keywords:

Chronic Kidney Disease, End-stage renal disease, Morbidity, Mortality

Abstract

This study evaluated the mortality among registered hemodialysis patients in a single center at Multan Institute Of Kidney Diseases (MIKD) Multan in south Punjab, Pakistan. A Retrospective cohort study was conducted at Multan Institute of Kidney Diseases, Multan, from 22 January 2019 to 22 December 2021 in three years. All adult patients of End-stage renal disease (ESRD) maintained on hemodialysis for more than three months registered with the dialysis unit of MIKD irrespective of their age, gender, serology with the biochemical test, morbidity, and cause of mortality were recorded in the study. SPSS version 22 was used for data entry and analysis. A p-value≥0.05 was considered significant. The ethical review committee approved the study ref# 08-14 dated 01-01-2022 to consent from all the included patients. Out of these 110 deaths, the mean age was 52.14±14.75, and male gender 80 (72.7%) were predominantly noted. Hypertension was the most common morbidity, followed by diabetes and diabetic nephropathy 103 (93.6%), 56 (50.9%), and 54 (49.1%), respectively. Predominant biochemical parameters of expired hemodialysis patients were hyperphosphatemia 64 (58.2%), anemia 51 (46.4%), hypoalbuminemia 43 (39.1%), hypocalcemia 35 (31.8%) and hypoparathyroidism 33 (30%). The leading cause of death was cardiovascular, 38 (34.5%). The most common viral marker in CVA was HBs Ag; HCV was the most common in CVD death patients (p<0.001).The relative risk of mortality in the HD population is 20.6 times to the general population. The risk variables can be monitored and intervened on in a timely manner to reduce mortality in the future.

Downloads

Download data is not yet available.

References

Abraham, G., Varughese, S., Thandavan, T., Iyengar, A., Fernando, E., Naqvi, S., Sheriff, R., Ur-Rashid, H., Gopalakrishnan, N., and Kafle, R. K. (2016). Chronic kidney disease hotspots in developing countries in South Asia. Clinical kidney journal 9, 135-141.

Ahmed, M., Alalawi, F., AlNour, H., Gulzar, K., and Alhadari, A. (2020). Five-Year Mortality Analysis in Hemodialysis Patients in a Single-Center in Dubai. Saudi Journal of Kidney Diseases and Transplantation 31, 1062.

Al Wakeel, J. S., Mitwalli, A. H., Al Mohaya, S., Abu-Aisha, H., Tarif, N., Malik, G. H., and Hammad, D. (2002). Morbidity and mortality in ESRD patients on dialysis. Saudi Journal of Kidney Diseases and Transplantation 13, 473.

Anees, M., Batool, S., Imtiaz, M., and Ibrahim, M. (2018). Socio-economic factors affecting quality of life of Hemodialysis patients and its effects on mortality. Pakistan Journal of Medical Sciences 34, 811.

Babitt, J. L., and Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology 23, 1631-1634.

Chan, W. K., Huang, L., Gudikote, J. P., Chang, Y. F., Imam, J. S., MacLean, J. A., and Wilkinson, M. F. (2007). An alternative branch of the nonsense‐mediated decay pathway. The EMBO journal 26, 1820-1830.

Chang, Y.-T., Wu, J.-L., Hsu, C.-C., Wang, J.-D., and Sung, J.-M. (2014). Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998–2009. Diabetes care 37, 277-285.

George, C., Mogueo, A., Okpechi, I., Echouffo-Tcheugui, J. B., and Kengne, A. P. (2017). Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ global health 2, e000256.

Giachelli, C. M. (2009). The emerging role of phosphate in vascular calcification. Kidney international 75, 890-897.

Ishii, J., Takahashi, H., Kitagawa, F., Kuno, A., Okuyama, R., Kawai, H., Muramatsu, T., Naruse, H., Motoyama, S., and Matsui, S. (2015). Multimarker approach to risk stratification for long-term mortality in patients on chronic hemodialysis. Circulation Journal, CJ-14-0915.

Javed, A., Ahmed, V., and Amal, B. K. (2021). The Social safety nets and poverty alleviation in Pakistan: an evaluation of livelihood enhancement and protection Programme. Britain International of Humanities and Social Sciences (BIoHS) Journal 3, 21-36.

Jha, V. (2013). Garcia⁃ Garcia G, Iseki K, et al. Chronic kidney disease.

Kasemy, Z. A., Hathout, H. M., Omar, Z. A., Samir, M. A., and Bahbah, W. A. (2020). Effect of Omega-3 supplements on quality of life among children on dialysis: a prospective cohort study. Medicine 99.

Kuo, K., Hung, S., Tseng, W., Tsai, M., Liu, J., Lin, M., Hsu, C., and Tarng, D. (2018). Taiwan Society of Nephrology Renal Registry Data. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM—HD Study. J. Am. Heart Assoc 7, e009206.

Li, P., Garcia-Garcia, G., Lui, S.-F., Andreoli, S., Fung, W., Hradsky, A., Kumaraswami, L., Liakopoulos, V., Rakhimova, Z., and Saadi, G. (2020). Kidney health for everyone everywhere–from prevention to detection and equitable access to care. Brazilian Journal of Medical and Biological Research 53.

Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-h., Lv, J., Garg, A. X., and Knight, J. (2015). Worldwide access to treatment for end-stage kidney disease: a systematic review. The Lancet 385, 1975-1982.

Norris, K., Mehrotra, R., and Nissenson, A. R. (2008). Racial differences in mortality and ESRD. American Journal of Kidney Diseases 52, 205-208.

Panday, V. B., Tong, Z.-P., Ng, P. L., Lee, E. J., Lau, T., Teo, B.-W., and Chua, H.-R. (2014). Dialysis modality and 2-year outcomes in patients with ischemic cardiomyopathy and end-stage renal disease. International journal of cardiology 176, 1097-1099.

Park, K. S., Ryu, G. W., Jhee, J. H., Kim, H. W., Park, S., Lee, S. A., Kwon, Y. E., Kim, Y. L., Ryu, H. J., and Lee, M. J. (2015). Serum ferritin predicts mortality regardless of inflammatory and nutritional status in patients starting dialysis: a prospective cohort study. Blood Purification 40, 209-217.

Robinson, B. M., Zhang, J., Morgenstern, H., Bradbury, B. D., Ng, L. J., McCullough, K. P., Gillespie, B. W., Hakim, R., Rayner, H., and Fort, J. (2014). Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney international 85, 158-165.

Swartling, O., Rydell, H., Stendahl, M., Segelmark, M., Lagerros, Y. T., and Evans, M. (2021). CKD progression and mortality among men and women: a nationwide study in Sweden. American Journal of Kidney Diseases 78, 190-199.